BTN3A1 and central nervous system cancer: To investigate the potential of enhancing the antitumor activity of Vγ9Vδ2 T cells in unsensitive glioma, we co-cultured Vγ9Vδ2 T cells with WAT primary glioma cells (TT-LS-luc, TT-YZJ-luc, TT-ZLH-luc, TT-XJ-luc, TT-SX-luc, and TT-HCL-luc) at E:T ratios of 1:1 in the presence or absence of ZOL or BTN3A1 agonistic antibody.